Jul 2026· International Immunopharmacology· Vol 186, pp.
117139
· 0 citations· 34 references
Medicine
TL;DR
It is suggested that Kinsenoside alleviates RPE cell injury under AMD-like stress, at least partly through exosome-associated modulation of JNK/MAPK signaling.
Abstract
Background
Dry age-related macular degeneration (AMD) is driven largely by retinal pigment epithelium (RPE) cell injury. Kinsenoside (KN) exhibits protective activity on RPE cells, but the direct effect on dry AMD and underlying molecular mechanisms remain unclear.
Objective
This study aimed to investigate the protective effects of KN against RPE cell injury and dysfunction in dry AMD and to elucidate its regulatory mechanisms.
Methods
An A2E- and blue light-induced ARPE-19 cell injury model and a blue light-induced AMD-like retinal injury mouse model were established. RPE cytotoxicity, apoptosis, senescence, inflammation, and melanogenesis-associated marker expression were evaluated. MAPK signaling was analyzed by Western blotting, and mechanistic analyses were performed using a JNK inhibitor, molecular docking analysis, an in vitro JNK enzymatic activity assay, exosome characterization, and exosome functional assays.
Results
KN treatment significantly attenuated cytotoxicity, apoptosis, cellular senescence, inflammatory responses, and melanogenesis-associated marker alterations in AMD-like ARPE-19 cells. In vivo, KN reduced drusen-like deposition, improved retinal structural integrity, and partially restored outer nuclear layer thickness while suppressing senescence and inflammation. Mechanistically, KN preferentially attenuated pathological JNK activation under the examined conditions and reduced JNK enzymatic activity in vitro. Pharmacological JNK inhibition phenocopied the protective effects of KN with no additive benefit, indicating pathway convergence. Exosome inhibition, transfer, and depletion experiments supported the contribution of exosome-associated signaling to KN-mediated cytoprotection.
Conclusion
These findings suggest that KN alleviates RPE cell injury under AMD-like stress, at least partly through exosome-associated modulation of JNK/MAPK signaling.
Cynarin protects against oxidative stress-induced retinal degeneration by suppressing MAPK and NF-κB inflammatory signaling, representing a promising therapeutic candidate for preventing or delaying NaIO3-induced dry AMD-like retinal injury.
Yue-Lin Fang, Y. Hsu, Chao-Hsien Sung et al.· Biomolecules· 0 citations
The iPSC-RPE/neuroretina co-culture is established as a platform to analyse pathophysiological features of AMD, dissect cell type-specific retinal responses to environmental stress and test neuroprotective pharmacological approaches to protect photoreceptors in oxidative stress-associated retinal degeneration.
Ana C. Almansa-Garcia, A. Armento, Shibu Antony et al.· bioRxiv· 0 citations
ALG attenuated oxidative stress-related retinal injury, and meanwhile retinal SIRT1 and Nrf2 expression increased, therefore, ALG may exert therapeutic effects against dAMD in association with SIRT1/Nrf2 upregulation.
Yan Xie, Peng He, Jufang Lv et al.· Phytomedicine· 0 citations
This study demonstrates that HKL protects against dry eye-associated corneal epithelial damage potentially through a mechanism involving SIRT3 modulation and PINK1-mediated mitophagy, offering a potential therapeutic strategy for dry eye disease.
Yu-Lei Huang, Xin-Dan Cao, Xin-Lin Yan et al.· Drug Design, Development and...· 0 citations
PSTX incubation blocked TRPM2-mediated Ca2+ signaling, reducing AMD-induced mitochondrial oxidant injury and cell death and PSTX, a new TRPM2 antagonist, may be utilized to treat oxidative stress and aberrant Ca2+ influx induced by AMD.
Dilek Özkaya, Mustafa Nazıroğlu· Graefe's archive for clinica...· 0 citations
Targeting the LPA1/USP1/ZEB1 axis may provide a promising therapeutic strategy for nAMD-associated SRF by driving RPE EMT through USP1-mediated deubiquitination and stabilization of ZEB1.
Manhui Zhu, Liang Cui, Yang Guo et al.· Investigative Ophthalmology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.